Search

Pathological cardiac hypertrophy serves as a significant foundation for cardiac dysfunction and heart failure. Recently, growing evidence has revealed that microRNAs (miRNAs) play multiple roles in biological processes and participate in cardiovascular diseases. In the present research, we investigate the impact of miRNA-34c-5p on cardiac hypertrophy and the mechanism involved. The expression of miR-34c-5p was proved to be elevated in heart tissues from isoprenaline (ISO)-infused mice. ISO also promoted miR-34c-5p level in primary cultures of neonatal rat cardiomyocytes (NRCMs). Transfection with miR-34c-5p mimic enhanced cell surface area and expression levels of foetal-type genes atrial natriuretic factor (Anf) and β -myosin heavy chain (β-Mhc) in NRCMs. In contrast, treatment with miR-34c-5p inhibitor attenuated ISO-induced hypertrophic responses. Enforced expression of miR-34c-5p by tail intravenous injection of its agomir led to cardiac dysfunction and hypertrophy in mice, whereas inhibiting miR-34c-5p by specific antagomir could protect the animals against ISO-triggered hypertrophic abnormalities. Mechanistically, miR-34c-5p suppressed autophagic flux in cardiomyocytes, which contributed to the development of hypertrophy. Furthermore, the autophagy-related gene 4B (ATG4B) was identified as a direct target of miR-34c-5p, and miR-34c-5p was certified to interact with 3′ untranslated region of Atg4b mRNA by dual-luciferase reporter assay. miR-34c-5p reduced the expression of ATG4B, thereby resulting in decreased autophagy activity and induction of hypertrophy. Inhibition of miR-34c-5p abolished the detrimental effects of ISO by restoring ATG4B and increasing autophagy. In conclusion, our findings illuminate that miR-34c-5p participates in ISO-induced cardiac hypertrophy, at least partly through suppressing ATG4B and autophagy. It suggests that regulation of miR-34c-5p may offer a new way for handling hypertrophy-related cardiac dysfunction. Isoprenaline promotes miR-34c-5p expression in cardiomyocytes, which inhibits autophagy by targeting ATG4B. The miR-34c-5p/ATG4B axis might be an important pathway contributing to the development of cardiac hypertrophy. [Display omitted] [ABSTRACT FROM AUTHOR]

Statement of problem Cobalt-chromium (Co-Cr) alloys have been widely used for metal-ceramic fixed prostheses and can be fabricated using conventionally cast or new computer-aided technology. However, the effect of different manufacturing methods on the metal-ceramic bond strength needs further evaluation. Purpose The purpose of this in vitro study was to evaluate the metal-ceramic bond strength of a Co-Cr alloy made by casting, milling, and selective laser melting (SLM). Material and methods Co-Cr specimens (25×3×0.5 mm) were prepared using a cast, milled, or SLM method and layered with ceramic (8×3×1.1 mm). Metal-ceramic bond strength was measured by a 3-point bend test according to ISO9693. The area fraction of adherence porcelain (AFAP) was determined by measuring the Si content of the specimens with scanning electron microscopy/energy dispersive spectroscopy (SEM/EDS). The metal-ceramic bond strength and AFAP results were analyzed using 1-way analysis of variance and the Bonferroni post hoc test (α=.05). SEM/EDS and metallurgic microscopy were also used to study the specimens’ morphology, elemental composition, and metallurgic structure. Results No significant differences ( P >.05) were found for the bond strength among cast, milled, and SLM Co-Cr alloys. The milled and SLM groups showed significantly more porcelain adherence than the cast group ( P <.001). The surface morphologies and oxidation characters of cast, milled, and SLM Co-Cr alloys were similar, whereas the metallurgic structures were different. Conclusions The bond strength between ceramics and Co-Cr alloys is independent of the manufacturing method. However, milling- and SLM-produced alloys had better porcelain adherence. [ABSTRACT FROM AUTHOR]

Abstract: The pathogens of Alzheimer''s disease (AD) are still unclear, while accumulating evidences have indicated that both genetic and environmental factors are involved in the pathogenesis of AD. Recent studies suggest that AD is primarily a vascular disorder and copper (Cu) may play an important role in AD pathology. However, the consequences of chronic Cu exposure at the presence of other AD risk factors remain to be clarified. To investigate the effects of chronic Cu intake on cerebral hypoperfusion-induced AD pathology, Sprague-Dawley rats suffered bilateral common carotid artery occlusion (2VO) were administrated with 250ppm copper-containing water or not. Morris water maze test showed that Cu exposure for 3 months exacerbated cognitive impairment induced by 2VO. Elevated amyloid precursor protein (APP) and beta-site APP-cleaving enzyme 1 (BACE1) expression in mRNA and protein levels were also observed in brain of Cu-exposed rats suffered 2VO. In contrast, these Cu-exacerbated changes were ameliorated after Cu was withdrawn from drinking water. In summary, our findings demonstrate that chronic Cu exposure might exacerbate AD pathology in 2VO rats. [Copyright &y& Elsevier]

Reduction in autophagy has been reported to contribute to the pathogenesis of cardiac hypertrophy. However, the molecular pathways leading to impaired autophagy at the presence of hypertrophic stimuli remain to be elucidated. The present study aimed to investigate the role of sirtuin 6 (SIRT6), a sirtuin family member, in regulating cardiomyocyte autophagy, and its implication in prevention of cardiac hypertrophy. Primary neonatal rat cardiomyocytes (NRCMs) or Sprague-Dawley (SD) rats were submitted to isoproterenol (ISO) treatment, and then the hypertrophic responses and changes in autophagy activity were measured. The influence of SIRT6 on autophagy was observed in cultured NRCMs with gain- and loss-of-function approaches to regulate SIRT6 expression, and further confirmed in vivo by intramyocardial delivery of an adenovirus vector encoding SIRT6 cDNA. In addition, the involvement of SIRT6-mediated autophagy in attenuation of cardiomyocyte hypertrophy induced by ISO was determined basing on genetic or pharmaceutical disruption of autophagy, and the underlying mechanism was preliminarily explored. ISO-caused cardiac hypertrophy accompanying with a significant decrease in autophagy activity. SIRT6 overexpression enhanced autophagy in NRCMs and in rat hearts, whereas knockdown of SIRT6 by RNA interference led to suppression of cardiomyocyte autophagy. Furthermore, the protective effect of SIRT6 against ISO-stimulated hypertrophy was associated with induction of autophagy. SIRT6 promoted nuclear retention of forkhead box O3 transcription factor possibly via attenuating Akt signaling, which was responsible for autophagy activation. Our findings revealed that SIRT6 positively regulates autophagy in cardiomyocytes, which may help to ameliorate ISO-induced cardiac hypertrophy. [ABSTRACT FROM AUTHOR]

Highlights: [•] In cardiomyocytes, ET-1 treatment resulted in significant upregulation of COX-2 expression and activity. [•] Both COX-2 inhibitors and COX-2 RNA interference suppressed cardiomyocyte hypertrophy induced by ET-1. [•] Calcineurin/NFATc3 signaling pathway participated in the transcriptional regulation of COX-2 by ET-1. [ABSTRACT FROM AUTHOR]

The reliability of wireless telecommunication service has become a major concern for the operation and maintenance (O&M) departments of the major telecommunication service providers. Consequently, reliability prediction has assumed a pivotal role for O&M department to furnish dependable services while simultaneously curtailing operational costs. However, predicting the service reliability is a challenging issue mainly attribute to the mobility characteristics of the end-users in the network. In tandem with the formulation of service reliability metrics, this study introduces a linear distribution regression model under Gaussian distribution and a kernel-based distribution regression model tailored for bimodal scenarios. The empirical validation of these proposed metrics and methodologies is substantiated through case studies employing both simulated data and real-world datasets derived from a wireless telecommunication system within an urban district. The outcomes of these case studies demonstrate the efficacy and applicability of the proposed metrics and methods. • Service reliability prediction for telecommunication network is considered. • A linear distribution regression is applied under Gaussian distribution. • A kernel-based distribution regression is proposed for bimodal distribution. • An adaptive algorithm is introduced to select the appropriate method. [ABSTRACT FROM AUTHOR]

Abstract Jumonji domain-containing protein D3 (JMJD3), a histone 3 lysine 27 (H3K27) demethylase, has been extensively studied for their participation in development, cellular physiology and a variety of diseases. However, its potential roles in cardiovascular system remain unknown. In this study, we found that JMJD3 played a pivotal role in the process of cardiac hypertrophy. JMJD3 expression was elevated by isoproterenol (ISO) stimuli both in vitro and in vivo. Overexpression of wild-type JMJD3, but not the demethylase-defective mutant, promoted cardiomyocyte hypertrophy, as implied by increased cardiomyocyte surface area and the expression of hypertrophy marker genes. In contrary, JMJD3 silencing or its inhibitor GSK-J4 suppressed ISO-induced cardiac hypertrophy. Mechanistically, JMJD3 was recruited to demethylate H3K27me3 at the promoter of β-MHC to promote its expression and cardiac hypertrophy. Thus, our results reveal that JMJD3 may be a key epigenetic regulator of β-MHC expression in cardiomyocytes and a potential therapeutic target for cardiac hypertrophy. Graphical abstract Image 1 Highlights • JMJD3 expression was significantly upregulated in ISO-induced cardiac hypertrophy in vitro and in vivo. • JMJD3 depletion or GSK-J4 treatment attenuated the hypertrophic responses stimulated by ISO. • JMJD3 overexpression led to cardiac hypertrophy. • JMJD3 was recruited to and demethylated H3K27me3 at the promoter of β-MHC to promote its expression and cardiac hypertrophy. [ABSTRACT FROM AUTHOR]

The Forkhead box-containing protein, O subfamily 3 (FoxO3) transcription factor negatively regulates myocardial hypertrophy, and its transcriptional activity is finely conditioned by diverse posttranslational modifications, such as phosphorylation, acetylation, ubiquitination, methylation and glycosylation. Here, we introduce a novel modification of the FoxO3 protein in cardiomyocytes: poly(ADP-ribosyl)ation (PARylation) mediated by poly(ADP-ribose) polymerase-1 (PARP1). This process catalyzes the NAD + -dependent synthesis of polymers of ADP-ribose (PAR) and their subsequent attachment to target proteins by PARPs. Primary-cultured neonatal rat cardiomyocytes were incubated with isoproterenol (ISO) to induce hypertrophy, or were infected with recombinant adenovirus vectors harboring PARP1 cDNA (Ad-PARP1). Sprague-Dawley (SD) rats were treated with ISO to induce cardiac hypertrophy, or were injected with Ad-PARP1 into the anterior and posterior left ventricular walls. Cardiomyocyte surface area, the mRNA expression of hypertrophic biomarkers, echocardiography, morphometry of the hearts were measured. The PARP1 activity was tested by cellular PAR levels. Interactions of PARP1 and FoxO3 were investigated by co-immunoprecipitation and immunofluorescence technique. PARylation of FoxO3 mediated by PARP1 facilitated its phosphorylation at the T32, S252 and S314 sites, triggered its nucleus export and suppressed its transcriptional activity and target genes expression, ultimately inducing cardiac hypertrophy. Additionally, PARP1 silencing or specific inhibition by 3-Aminobenzamide (3AB) and veliparib (ABT-888) alleviated the inhibition of FoxO3 activity by ISO, thus suppressing ISO-induced cardiac hypertrophy. Our data provide the first evidence that PARP1 exacerbates cardiac hypertrophy by PARylation of FoxO3. [ABSTRACT FROM AUTHOR]

Objective Tongue squamous cell carcinoma (TSCC) is the most common malignant cancer in the oral cavity, with a high rate of metastasis to the neck lymphoid node. Angiopoietin-like protein 4 (ANGPTL4) and microvessel density (MVD) may be novel indicators for tumor metastasis. The aim of the present study was to investigate the expression and function of ANGPTL4 in TSCC and the relationship between ANGPTL4 and MVD. Methods The expression levels of ANGPTL4 and MVD (CD34) were analyzed in 65 TSCC specimens and the adjacent non-cancerous tissues using immunohistochemistry (IHC). siRNA was delivered into TSCCA cells to downregulate ANGPTL4 expression. Subsequently, validation with real-time RT-PCR and western blot analyses was performed to analyze ANGPTL4 expression levels. In addition, a proliferation assay, migration and invasion assays were carried out. Results ANGPTL4 expression was associated with tumor stage, lymph node metastasis and MVD expression. Cox regression analysis showed that high levels of ANGPTL4 expression were closely associated with poor survival time. In vitro analyses using qRT-PCR and western blot confirmed that ANGPTL4 was successfully inhibited in TSCCA cells. Suppressing ANGPTL4 resulted in the inhibition of cell proliferation and migration, but neither invasion nor cisplatin resistance was significantly affected. Conclusion High expression levels of ANGPTL4 are associated with the T stage, lymphatic metastasis, angiogenesis and poor overall survival in TSCC patients. The downregulation of ANGPTL4 inhibits the migration and proliferation of cells in TSCC. Taken together, ANGPTL4 may serve as a novel biomarker and therapeutic target for TSCC. [ABSTRACT FROM AUTHOR]

Highlights: [•] C/EBPβ expression is upregulated in response to hypertrophic stimulation in vitro and in vivo. [•] C/EBPβ knockdown protects cardiomyocytes from hypertrophy. [•] C/EBPβ knockdown reduced the nuclear translocation of p65-NFκB, and diminished NFκB-DNA binding activity. [ABSTRACT FROM AUTHOR]

Highlights: [•] Fenofibrate ameliorates cardiac hypertrophy in vivo and in vitro. [•] The interaction between p65-NFκB and NFATc4 regulates cardiac hypertrophy. [•] Fenofibrate attenuates cardiac hypertrophy via activating PPAR-α and thereby preventing the association of p65-NFκB with NFATc4. [Copyright &y& Elsevier]